
Sign up to save your podcasts
Or


Best practices for hospital-based initiation of medications for opioid use disorder: A consensus statement
JAMA Network Open
This survey study used a 2-round Delphi process to develop expert consensus on best practices for hospital-based MOUD initiation for patients with OUD, with a goal to provide guidance on changing inpatient addiction treatment in response to increased synthetic opioids in the unregulated drug supply. A total of 42 expert clinicians participated; clinicians were considered a national expert if they had cared for at least 100 hospitalized patients with OUD in the last two years. There was consensus that buprenorphine and methadone initiation in the hospital setting were appropriate, with less support for hospital-based naltrexone initiation. Consensus was also reached to support rapid methadone initiation; high- and low-dose buprenorphine initiation; and provision of non-MOUD full agonist opioids for treatment of opioid withdrawal during methadone initiation, as a bridge to buprenorphine initiation, and for those declining MOUD.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
By American Society of Addiction Medicine4.9
77 ratings
Best practices for hospital-based initiation of medications for opioid use disorder: A consensus statement
JAMA Network Open
This survey study used a 2-round Delphi process to develop expert consensus on best practices for hospital-based MOUD initiation for patients with OUD, with a goal to provide guidance on changing inpatient addiction treatment in response to increased synthetic opioids in the unregulated drug supply. A total of 42 expert clinicians participated; clinicians were considered a national expert if they had cared for at least 100 hospitalized patients with OUD in the last two years. There was consensus that buprenorphine and methadone initiation in the hospital setting were appropriate, with less support for hospital-based naltrexone initiation. Consensus was also reached to support rapid methadone initiation; high- and low-dose buprenorphine initiation; and provision of non-MOUD full agonist opioids for treatment of opioid withdrawal during methadone initiation, as a bridge to buprenorphine initiation, and for those declining MOUD.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

701 Listeners

141 Listeners

2,455 Listeners

3,374 Listeners

30 Listeners

1,363 Listeners

296 Listeners

566 Listeners

489 Listeners

14,324 Listeners

56 Listeners

126 Listeners

63 Listeners

31 Listeners

21 Listeners